Australia - English - Department of Health (Therapeutic Goods Administration)

mecca brands pty ltd -

United States - English - NLM (National Library of Medicine)

ligand pharmaceuticals incorporated - alitretinoin (unii: 1ua8e65kdz) (alitretinoin - unii:1ua8e65kdz) - gel - 1 mg in 1 g - panretin® gel is indicated for topical treatment of cutaneous lesions in patients with aids-related kaposi’s sarcoma. panretin® gel is not indicated when systemic anti-ks therapy is required (e.g., more than 10 new ks lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary ks, or symptomatic visceral involvement). there is no experience to date using panretin® gel with systemic anti-ks treatment. panretin® gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.

United States - English - NLM (National Library of Medicine)

eisai inc. - alitretinoin (unii: 1ua8e65kdz) (alitretinoin - unii:1ua8e65kdz) - alitretinoin 60 mg in 60 g - panretin® gel is indicated for topical treatment of cutaneous lesions in patients with aids-related kaposi’s sarcoma. panretin® gel is not indicated when systemic anti-ks therapy is required (e.g., more than 10 new ks lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary ks, or symptomatic visceral involvement). there is no experience to date using panretin® gel with systemic anti-ks treatment. panretin® gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.

United States - English - NLM (National Library of Medicine)

concordia pharmaceuticals inc. - alitretinoin (unii: 1ua8e65kdz) (alitretinoin - unii:1ua8e65kdz) - panretin® gel is indicated for topical treatment of cutaneous lesions in patients with aids-related kaposi’s sarcoma. panretin® gel is not indicated when systemic anti-ks therapy is required (e.g., more than 10 new ks lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary ks, or symptomatic visceral involvement). there is no experience to date using panretin® gel with systemic anti-ks treatment. panretin® gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.

Australia - English - Department of Health (Therapeutic Goods Administration)

mecca brands pty ltd -

Canada - English - Health Canada

bausch health, canada inc. - betamethasone (betamethasone valerate); gentamicin (gentamicin sulfate) - cream - 0.1%; 0.1% - betamethasone (betamethasone valerate) 0.1%; gentamicin (gentamicin sulfate) 0.1% - antibiotics

Canada - English - Health Canada

bausch health, canada inc. - betamethasone (betamethasone valerate); gentamicin (gentamicin sulfate) - ointment - 0.1%; 0.1% - betamethasone (betamethasone valerate) 0.1%; gentamicin (gentamicin sulfate) 0.1% - antibiotics

Australia - English - Department of Health (Therapeutic Goods Administration)

mecca brands pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

mecca brands pty ltd -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

bayer -